TY - JOUR
T1 - Preliminary study on the relationship between serum zinc levels and atopic dermatitis in children
AU - Zhang, Sheng Ni
AU - Zhang, Tao
AU - Ding, Qiu Yun
AU - Wang, Yong Qiang
AU - Zhao, Jian Wei
AU - Tian, Wen Ying
PY - 2015/7/5
Y1 - 2015/7/5
N2 - Objective: To explore the relationship between serum zinc levels and atopic dermatitis (AD) in children. Methods: From March 2012 to September 2014, 62 children with AD were randomly divided into two groups (zinc supplemental and non zinc supplemental group). 50 healthy children served as normal controls. Eczema assessment severity index (EASI), visual analogue scale (VAS), scoring atopic dermatitis (SCORAD), serum zinc and IgE levels were assessed before and after treatment. Results: In comparison with normal controls, the baseline zinc levels were significantly lower in AD patients (P=0.015), while the total IgE levels were higher (P=0.023). After zinc supplement, serum zinc levels in zinc supplemental group were higher than that in non zinc supplemental group. After 8 weeks of treatment, the total IgE levels differed significantly among three groups (62.78±13.79 kU/L in zinc supplemental group; 119.68±15.89 kU/L in non supplemental group, and 56.82±24.65 kU/L in normal controls, P<0.05 between groups). After 4 weeks and 8 weeks of treatment, the differences of EASI, VAS and SCORAD were significant between zinc supplemental and non zinc supplemental group (P<0.05). Moreover, after 8 weeks of zinc supplement, EASI, VAS and SCORAD were markedly improved from baseline (P<0.05). Conclusions: Zinc deficiency may be a risk factor for AD. Oral zinc supplement can improve the clinical symptoms of AD. It is an optional regimen for AD.
AB - Objective: To explore the relationship between serum zinc levels and atopic dermatitis (AD) in children. Methods: From March 2012 to September 2014, 62 children with AD were randomly divided into two groups (zinc supplemental and non zinc supplemental group). 50 healthy children served as normal controls. Eczema assessment severity index (EASI), visual analogue scale (VAS), scoring atopic dermatitis (SCORAD), serum zinc and IgE levels were assessed before and after treatment. Results: In comparison with normal controls, the baseline zinc levels were significantly lower in AD patients (P=0.015), while the total IgE levels were higher (P=0.023). After zinc supplement, serum zinc levels in zinc supplemental group were higher than that in non zinc supplemental group. After 8 weeks of treatment, the total IgE levels differed significantly among three groups (62.78±13.79 kU/L in zinc supplemental group; 119.68±15.89 kU/L in non supplemental group, and 56.82±24.65 kU/L in normal controls, P<0.05 between groups). After 4 weeks and 8 weeks of treatment, the differences of EASI, VAS and SCORAD were significant between zinc supplemental and non zinc supplemental group (P<0.05). Moreover, after 8 weeks of zinc supplement, EASI, VAS and SCORAD were markedly improved from baseline (P<0.05). Conclusions: Zinc deficiency may be a risk factor for AD. Oral zinc supplement can improve the clinical symptoms of AD. It is an optional regimen for AD.
KW - Atopic dermatitis
KW - IgE
KW - Serum zinc
UR - http://www.scopus.com/inward/record.url?scp=84947217583&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84947217583
SN - 1000-4963
VL - 44
SP - 413
EP - 416
JO - Journal of Clinical Dermatology
JF - Journal of Clinical Dermatology
IS - 7
ER -